52 North Health
United Kingdom
activeseries-c-plus
series-c-plus
Stage
2020
Founded
1
Investors
About
52 North Health develops affordable, patient-centered medical technology solutions for cancer patients, primarily focusing on the NeutroCheck device, which uses a finger-prick blood test and AI to monitor risk of neutropenic sepsis in patients undergoing chemotherapy, enabling at-home monitoring and improving health outcomes and equity.
Explore 52 North Health's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.